💊 Thuốc A-Z 🧬 Đích tác dụng 🛠 Công cụ 📚 Hướng dẫn
Tất cả thuốc Phân loại thuốc Lĩnh vực điều trị Tác dụng phụ
Hướng dẫn Từ điển thuật ngữ Dòng thời gian
So sánh Hành trình của thuốc Các họ thuốc
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Sargramostim

CHEMBL1201670 Phase 4 Đã phê duyệt Protein
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
— g/mol
LogP
—
Phase
4

Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the proliferation, differentiation, and activation of hematopoietic progenitor cells, particularly granulocytes and monocytes/macrophages. It is used to accelerate myeloid recovery following bone marrow transplantation, treat neutropenia in cancer patients, and mobilize peripheral blood stem cells for collection. Investigational applications include Alzheimer's disease, where GM-CSF may stimulate microglial amyloid clearance.

Lĩnh vực điều trị

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Endocrinology Non-Small Cell Lung Cancer Alzheimer's Disease Parkinson's Disease Melanoma Oncology Lymphoma Hypertension Breast Cancer HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Cơ chế tác dụng

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

Sargramostim is a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) that stimulates the proliferation, differentiation, and activation of hematopoietic progenitor cells, particularly granulocytes and monocytes/macrophages. It is used to accelerate myeloid recovery following bone marrow transplantation, treat neutropenia in cancer patients, and mobilize peripheral blood stem cells for collection. Investigational applications include Alzheimer's disease, where GM-CSF may stimulate microglial amyloid clearance.

As a recombinant protein, it replicates the function of the naturally occurring human protein, supplementing or replacing deficient endogenous production to restore normal physiological activity.

Yes, Sargramostim is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201670. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.